Roche inks potential $3B multi-target strategic collaboration with Shape Therapeutics

  • Roche (OTCQX:RHHBY) has signed a multi-target strategic collaboration and license agreement with Shape Therapeutics.
  • Under the terms of the agreement, Shape is eligible to receive an initial payment as well as development, regulatory and sales milestone payments, potentially exceeding $3B in aggregate value.
  • Shape will apply its proprietary RNA editing platform RNAfix and its AAVid technology platform for next-generation tissue-specific adeno-associated viruses ((AAVs)) for the development of gene therapy for certain targets in the areas of Alzheimer's disease, Parkinson's disease, and rare diseases.
  • During the course of the partnership, Shape will conduct preclinical research to identify and deliver development candidates discovered by its AI-powered platforms RNAfix and, potentially, AAVid.
  • Roche will be responsible for the development and worldwide commercialization of any potential products resulting from the collaboration.
  • Shape is also eligible to receive tiered royalties on future sales of products resulting from the collaboration.

    Over the current book year the company from Basel's total revenue could be around 61.84 billion CHF (consensus estimates). This is slightly more than 2021's revenue of 58.32 billion CHF.

    Historical revenues and results Roche plus estimates 2021

    fundamenteel onderzoek

    The analysts expect for 2021 a net profit of 16.96 billion CHF. For this year most of the analysts expect a profit per share of 19.91 CHF. The PE-ratio therefore is 18.46.

    Per share the analysts expect a dividend of 9.38 CHF per share. Roche 's dividend yield thus equals 2.55 percent. The average dividend yield of the pharmaceutical companies equals a moderate 1.37 percent.

    Recent target prices around 368 CHF

    The most recent recommendations for the pharmaceutical company are from JP Morgan, Credit Suisse and Barclays .

    Roche 's market capitalization is based on the number of outstanding shares around 255.76 billion CHF. 17

    At 14.37 the stock trades 0.71 percent lower at 367.6 CHF.

    Historical stock prices Roche from 2007 till 2021

    fundamental research roche News Wire & Equity Research: +31 084-0032-842

    Copyright B.V.
    All rights reserved. Any redistribution, duplication or archiving prohibited. doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.